Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH

Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH is a protected amino acid dipeptide-building-block style derivative featuring an N-terminal Fmoc carbamate and a side-chain-protected serine residue bearing a Psi(Me,Me)pro substituent. The molecule combines a leucine stereocenter and a serine stereocenter with a constrained side-chain motif designed to modulate hydrogen-bonding and conformational behavior relative to unmodified Ser. The Fmoc group enables base-labile N-deprotection for stepwise peptide assembly, while the serine side-chain protecting strategy is engineered to withstand common peptide coupling conditions and to control the functional group presentation at the serine position. The presence of amide-forming functionality at the carboxy terminus and the protected side-chain oxygen surrogate supports downstream derivatization into peptide analogs and structure-defined synthetic intermediates for peptide science and process-oriented manufacturing workflows.

1. Peptide Synthesis

Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH is suitable for automated and manual solid-phase peptide synthesis workflows where Fmoc deprotection and subsequent amide bond formation are required at the N-terminus. The leucine backbone provides a hydrophobic side-chain that participates in standard peptide coupling chemistry, while the serine residue is presented in a protected form that preserves the side-chain modification during chain elongation. The Psi(Me,Me)pro side-chain protection strategy can be applied to construct peptide sequences with controlled serine-like positioning and altered local polarity, supporting the preparation of peptide building blocks for analog libraries. The resulting protected amino acid derivative can be incorporated into longer peptide chains to generate sequence-defined products for biochemical research and synthetic method development.

2. Peptidomimetics

Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH is relevant to peptidomimetic construction because the Psi(Me,Me)pro-modified serine side chain can function as a conformationally tuned surrogate for native Ser hydroxyl chemistry. The Fmoc-protected N-terminus enables incorporation into peptide-like scaffolds while maintaining compatibility with peptide coupling and protecting-group orthogonality. The leucine residue contributes hydrophobic packing features that can influence secondary structure propensity and binding-site complementarity in peptide analogs. The compound can be used to generate structure-activity relationship focused libraries where side-chain electronics and steric profile are systematically varied through protected amino acid incorporation.

3. Chemical Biology

Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH can be employed in chemical biology research to prepare defined peptide probes with controlled side-chain functionality at the serine position. The protected serine motif supports the assembly of peptides that may later undergo selective deprotection or functional group transformation to enable downstream conjugation handles, affinity tags, or reactivity modulation. The N-terminal Fmoc group supports stepwise synthesis of labeled or modified peptide segments with minimal side reactions during chain assembly. The resulting peptide products derived from this amino acid building block can serve as molecular tools for studying recognition events, substrate-like interactions, and sequence-dependent biochemical behavior in controlled experimental settings.

4. SAR Studies

Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH is applicable to structure-activity relationship studies where precise stereochemical placement of leucine and a Psi(Me,Me)pro-modified serine residue is required to interrogate structure-function effects. The chiral centers preserved in the protected amino acid framework enable consistent stereochemical identity across analog series, supporting meaningful comparisons between closely related peptide variants. The side-chain protection strategy helps maintain the intended serine surrogate during synthesis, reducing variability introduced by competing functional group reactivity. The compound can be incorporated into peptide analog panels to generate reproducible molecular scaffolds for SAR mapping and for refining design hypotheses in peptide-driven medicinal chemistry programs.

5. Pharmaceutical Manufacturing

Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH supports pharmaceutical manufacturing workflows that rely on protected amino acid intermediates for controlled peptide intermediate preparation and scalable peptide synthesis. The Fmoc carbamate provides a standardized, base-labile N-protection handle that aligns with common industrial peptide assembly strategies, enabling reliable deprotection and coupling cycles. The Psi(Me,Me)pro side-chain protection architecture is designed to endure typical peptide synthesis conditions while preserving the intended serine substitution pattern for downstream processing. The compound can serve as a defined input material for producing peptide intermediates and drug-substance precursors where stereochemical integrity and protecting-group orthogonality are required for consistent batch-to-batch synthetic outcomes.

6. Process Chemistry Intermediate

Fmoc-Leu-Ser(Psi(Me,Me)pro)-OH functions as a process chemistry intermediate for fine chemical synthesis routes that require protected amino acid derivatives with predictable reactivity profiles. The terminal carboxylic acid enables conversion into activated coupling forms under standard peptide-manufacturing conditions, while the Fmoc group provides a controlled deprotection step that can be integrated into manufacturing sequences. The leucine and Psi(Me,Me)pro-modified serine stereochemical framework can be used to design robust downstream transformations into peptide fragments, protected peptide segments, or intermediate precursors for larger molecules. The compound's protected functional groups support reproducible handling and purification logic typical of industrial peptide intermediate production, linking amino acid derivatization chemistry to scalable synthetic execution.

1. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

2. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

3. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

4. TMEM16F and dynamins control expansive plasma membrane reservoirs

5. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die